Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium azulenesulfonate (also known as sodium gualenate) is a water-soluble derivative of azulene, a natural anti-inflammatory compound extracted from chamomile (*Matricaria chamomilla*). It is widely used as a mucosal protective and anti-inflammatory agent to treat gastrointestinal disorders, such as chronic gastritis, gastric ulcers, and duodenal ulcers, as well as localized inflammatory conditions of the mouth and throat (e.g., pharyngitis, tonsillitis, stomatitis). Sodium azulenesulfonate exerts its therapeutic effects by directly acting on inflamed mucosal tissues to inhibit histamine release from mast cells, reduce pepsin activity, and increase mucosal prostaglandin E2 synthesis, which promotes granulation tissue formation and epithelial cell regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium azulenesulfonate.